Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (45)

1

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON) : An International Real-World Safety and Efficacy Analysis

enthalten in: International journal of molecular sciences | 2024

von Illini, O. | Saalfeld, F. | Christopoulos, P. | +45

2

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer : An Open-Label, Single-Arm, Phase 2 Study

enthalten in: International journal of radiation oncology, biology, physics | 2023

von Peled, N. | Roisman, L. | Levison, E. | +22

CommentIn: Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):115-117. - PMID 37574235

3

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer : A large real-world cohort and review of the literature

enthalten in: Thoracic cancer | 2023

von Averbuch, I. | Tschernichovsky, R. | Icht, O. | +9

4

Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer : Characterization and Correlation with Response to Therapy

enthalten in: Biomedicines | 2023

von Rotem, O. | Zer, A. | Yosef, L. | +11

5

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer : A Population-Based Cohort Study

enthalten in: The oncologist | 2023

von Icht, O. | Leader, A. | Batat, E. | +8

6

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer : impact on response to therapy and disease course

enthalten in: Translational lung cancer research | 2023

von Tschernichovsky, R. | Averbuch, I. | Goldstein, D. | +7

7

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

enthalten in: Journal of clinical medicine | 2022

von Raphael, A. | Dudnik, E. | Hershkovitz, D. | +10

8

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50

enthalten in: Clinical lung cancer | 2022

von Holtzman, L. | Moskovitz, M. | Urban, D. | +10

9

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

enthalten in: The oncologist | 2022

von Moskovitz, M. | Dudnik, E. | Shamai, S. | +13

10

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program

enthalten in: Therapeutic advances in medical oncology | 2022

von Illini, O. | Fabikan, H. | Swalduz, A. | +28

1
2
3
4
5
Nächster »
[5]